In the last decade, therapies used to treat children with acute lymphocytic leukemia (ALL) have improved the survival rates dramatically, but they also cause genetic mutations in the children. A new study reports that the treatments cause a high rate of mutations and says that the genetic damage persists in the children long after the cancer is in remission.
